Potential Marker for Response to Anti-EGFR Therapy in KRAS Wild-Type Metastatic Colorectal Cancer

Get Permission

As reported in Clinical Cancer Research, Manceau and colleagues attempted to identify microRNAs that can predict response to anti-EGFR therapy in wild-type KRAS metastatic colorectal cancer patients.

Initial screening of 1,145 microRNAs in fresh frozen tumor samples from chemotherapy-refractory metastatic colorectal cancer patients who were treated with anti-EGFR therapy showed a significant association between has-miR-131-3p expression and progression-free survival. Studies in vitro identified a total of 47 genes regulated by hsa-miR-31-3p. Statistical models based on has-miR-131-3p expression discriminated high vs low risk of progression in both fresh frozen and formalin-fixed paraffin embedded (FFPE) samples.

The models were confirmed in a validation cohort for both fresh frozen (hazard ratio [HR] = 4.1, P < .04) and FFPE samples (HR = 2.44, P = .028). The percentage of variation in RECIST responses in the validation cohort was significantly associated with both level of hsa-miR-31-3p expression (r2 = 0.49, P = .0035) and risk status based on expression level (P = .02). The investigators constructed and validated nomograms to predict progression-free survival based on hsa-miR-31-3p expression level.

The investigators concluded, “Hsa-miR-31-3p appears to be a new [metastatic colorectal cancer] biomarker whose expression level allows for the identification of patients with wild-type KRAS [metastatic colorectal cancer] who are more likely to respond to anti-EGFR therapy.” ■

Manceau G, et al: Clin Cancer Res 20:3338-3347, 2014.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.